Pinnacle Food Group Limited Announces Breakthrough in Recombinant Human Lactoferrin (rhLF) Production Using Cost-Effective, Methanol-Free Fermentation Method

Pinnacle Food Group (Nasdaq: PFAI) announced a technical milestone on April 15, 2026: its research team developed a first‑generation recombinant yeast strain to produce human lactoferrin (rhLF) using a patented methanol-free Pichia fermentation method.

Rhea-AI Summary

Pinnacle Food Group (Nasdaq: PFAI) announced a technical milestone on April 15, 2026: its research team developed a first‑generation recombinant yeast strain to produce human lactoferrin (rhLF) using a patented methanol-free Pichia fermentation method.

The platform eliminates methanol, reducing fire-hazard CapEx needs, removes toxic residues for infant‑nutrition and pharma uses, and has been pilot-validated on other proteins, supporting scale-up potential.

Argus Apr 15 session

+1.04% close to close Open Argus

Details

News Market Reaction – PFAI

In the Apr 15 session, PFAI gained 1.04%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a concrete technical step in Pinnacle Food Group’s bioengineering strat...

Analysis

This announcement highlights a concrete technical step in Pinnacle Food Group’s bioengineering strategy: a methanol-free Pichia platform generating recombinant human lactoferrin for high-purity nutrition and pharmaceutical uses. It builds on earlier moves, including the 18‑month Bioboost collaboration and lab expansion initiatives. Investors may track further strain optimization, pilot-scale runs, and eventual commercial manufacturing updates, as well as how this bioengineering “Engine 2” complements the existing smart agriculture revenue base over time.

Key Figures

Bioboost payments: $580,000 Development period: 18 months Current price: $3.86 +5 more

Bioboost payments

$580,000

Milestone-based payments under 18‑month Bioboost collaboration (6-K, Jan 28, 2026)

Development period

18 months

Length of Bioboost precision fermentation collaboration (6-K, Jan 28, 2026)

Current price

$3.86

Pre-news trading level on 2026-04-15

52-week range

$1.30 – $4.93

Low and high before this announcement

Market cap

$45,103,500

Equity value prior to this news

Volume today

3,071 shares

Compared with 20-day average volume of 7,885 shares

Price vs 52-week high

-21.7%

Distance from 52-week high before this news

Price vs 52-week low

196.92%

Gain versus 52-week low before this news

Historical Context

4 past events · Latest: Mar 13

4 events

1. Mar 13

   Investor Day recap

   24h Move

   -3.3%

   Virtual Investor Day highlighting Dual-Engine growth and rhLF commercialization plans.

2. Mar 02

   Investor Day invite

   24h Move

   +2.2%

   Announcement of upcoming Investor Day 2026 and non-deal roadshow schedule.

3. Jan 28

   Biotech collaboration

   24h Move

   +6.8%

   Subsidiary enters Bioboost collaboration on precision fermentation and rhLF applications.

4. Nov 24

   Bioengineering initiative

   24h Move

   +0.0%

   Launch of strategic initiative to build bioengineering and testing lab with Bioboost support.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

recombinant human lactoferrin, precision fermentation, pichia fermentation, methanol-free, +1 more

5 terms

recombinant human lactoferrin medical

"created the first generation of a recombinant yeast strain to produce human lactoferrin (rhLF)"

A lab-made version of a naturally occurring human protein that helps bind iron and supports immune and gut health; it is produced by genetically engineered cells to be identical to the human form. Investors watch it because its safety, manufacturing cost and regulatory approval determine whether it can be sold in foods, supplements or medicines—think of it as a factory-made copy of a natural ingredient whose market value depends on demand, evidence and production scalability.

precision fermentation medical

"a significant technical milestone in its precision fermentation R&D pipeline achieved at its laboratory"

Precision fermentation uses edited microbes (like yeast or bacteria) as tiny, programmable factories to produce a single, specific ingredient—such as a protein, enzyme or flavor—rather than making whole foods. Think of it like coding a vending machine to dispense one exact product on demand. For investors, it matters because it can cut production costs, speed up scale-up, reduce reliance on traditional agriculture or chemical synthesis, and create new, high-margin products that can reshape markets and regulatory pathways.

pichia fermentation medical

"using a patented methanol-free Pichia fermentation method, accessed through the Company's research"

Pichia fermentation is the process of using Pichia, a type of single‑celled yeast, grown in controlled tanks to produce proteins, enzymes or other biological ingredients. For investors, it matters because this method can scale up production cost‑effectively and reliably—similar to using a high‑yield recipe and oven to bake many loaves—so success or problems in Pichia processes affect manufacturing costs, supply reliability and regulatory review for biologic products.

methanol-free technical

"this advanced platform eliminates methanol to fundamentally mitigate severe fire hazards"

Methanol-free describes products, fuels or manufacturing processes that do not contain methanol, a volatile and toxic alcohol used as a solvent, fuel additive or chemical feedstock. For investors it matters because avoiding methanol can reduce regulatory hurdles, liability and handling costs, affect product labeling and market access, and change margins or supply dynamics — similar to choosing a non-toxic cleaner that is safer but may cost or perform differently.

glycoprotein medical

"It is a bioengineered, iron-binding glycoprotein structurally similar to natural human milk protein."

A glycoprotein is a protein that carries short sugar chains attached to its surface, like a coat with name tags that change how it behaves and how the body recognizes it. Investors care because these molecules often control key biological interactions—serving as drug targets, vaccine ingredients or diagnostic markers—so advances or setbacks involving glycoproteins can directly affect the value and prospects of biotech and pharmaceutical companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, BC and HONG KONG, April 15, 2026 /PRNewswire/ -- Pinnacle Food Group Limited (Nasdaq: PFAI), a technology-driven company operating at the intersection of smart agriculture and bio-engineering, today announced a significant technical milestone in its precision fermentation R&D pipeline achieved at its laboratory in Hong Kong.

The research team created the first generation of a recombinant yeast strain to produce human lactoferrin (rhLF) using a patented methanol-free Pichia fermentation method, accessed through the Company's research collaboration with Bioboost. Unlike traditional fermentation which relies on methanol—a highly flammable, toxic solvent that requires massive capital expenditure (CapEx) for explosion-proof facilities—this advanced platform eliminates methanol to fundamentally mitigate severe fire hazards and substantially reduce operational costs. It also ensures zero toxic residue, a critical advantage for high-purity infant nutrition and pharmaceutical applications. While the rhLF strain continues to advance, the underlying methanol-free technology platform has already been successfully validated with other protein targets at pilot scale, demonstrating its robust readiness for commercial manufacturing.

Human lactoferrin (rhLF) is a high-value functional protein widely sourced by manufacturers in infant nutrition, dietary supplements, and pharmaceutical applications. It is a bioengineered, iron-binding glycoprotein structurally similar to natural human milk protein.

Jiulong You, Chief Executive Officer of Pinnacle Food Group Limited, commented: "This breakthrough marks a critical step forward in our bio-engineering strategy, validating our technical capabilities and accelerating our path toward becoming a premier business-to-business (B2B) manufacturer and supplier of high-value biological ingredients for our industry partners."

About Pinnacle Food Group Limited

Pinnacle Food Group Limited (Nasdaq: PFAI) is a technology-driven company operating at the intersection of smart agriculture and bio-engineering. Driven by a "Dual-Engine" strategy, the Company integrates advanced Farming-as-a-Service (FaaS) solutions with cutting-edge precision fermentation and synthetic biology platforms to build highly efficient and sustainable food systems. For more information, please visit the Company's website at www.pinnaclefoodinc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. federal securities laws, including statements regarding the Company's expectations, research milestones, and the anticipated scalability of its fermentation process. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pinnacle-food-group-limited-announces-breakthrough-in-recombinant-human-lactoferrin-rhlf-production-using-cost-effective-methanol-free-fermentation-method-302741094.html

SOURCE Pinnacle Food Group Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pinnacle Food Group (PFAI) announce on April 15, 2026 about rhLF production?

They announced a first-generation recombinant yeast strain producing human lactoferrin using a patented methanol-free Pichia method. According to the company, this avoids methanol, lowers fire-hazard CapEx and yields zero toxic residue suitable for infant nutrition and pharmaceutical applications.

How does the methanol-free fermentation method affect Pinnacle Food Group's manufacturing costs and safety?

The method reduces the need for explosion-proof methanol facilities and associated CapEx and operational risk. According to the company, eliminating methanol mitigates severe fire hazards and substantially reduces operating costs versus traditional methanol-based processes.

Is Pinnacle Food Group's methanol-free platform validated for commercial use for PFAI?

The platform has been validated at pilot scale for other protein targets, indicating readiness for commercial manufacturing. According to the company, pilot-scale success demonstrates the platform's robustness while rhLF strain development continues in Hong Kong labs.

Why is zero toxic residue important for Pinnacle Food Group's rhLF product (PFAI)?

Zero toxic residue is critical for infant nutrition and pharmaceutical markets where purity matters. According to the company, the methanol-free process ensures high-purity rhLF, improving suitability for sensitive B2B ingredient customers and regulatory expectations.

What strategic impact did CEO Jiulong You say the PFAI breakthrough has on the company?

The CEO described the breakthrough as a critical step validating technical capabilities and accelerating B2B manufacturing ambitions. According to the company, this advances their strategy to become a supplier of high-value biological ingredients to industry partners.